1. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells;Karschnia;Blood,2019
2. Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) [abstract];Locke;Blood,2017
3. Total costs of chimeric antigen receptor T-cell immunotherapy;Hernandez;JAMA Oncol,2018
4. Estimation of the resource utilization and costs of cytokine release syndrome observed in the transcend-NHL clinical trial: a micro-costing study [abstract];Siddiqi;Blood,2018